drugset / Trial / NCT03928158
LCZ696 in Advanced LV Hypertrophy and HFpEF
Phase 2
Completed
61 enrolled
National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
RandomizedParallel-groupOpen-labelTreatment
Summary
Patients with advanced LVH and HFpEF will be randomly assigned in open-label fashion to receive LCZ696 titrated to 200 mg twice daily or valsartan titrated to 160 mg twice daily, and will be treated for 24 weeks.
Timeline
- Start
- 2019-05-31
- Primary completion
- 2023-06-30
- Completion
- 2023-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LCZ696 | Unknown | 200 mg | — |
| Comparator | Valsartan | Small molecule | 160 mg | — |